Safety and Immunogenicity of a Candidate MERS-CoV Viral-Vectored Vaccine
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Infectious Diseases
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and Immunogenicity of a Candidate Middle East Respiratory Syndrome Coronavirus Viral-Vectored Vaccine: A Dose-Escalation, Open-Label, Non-Randomised, Uncontrolled, Phase 1 Trial
Lancet Infect Dis 2020 Apr 20;[EPub Ahead of Print], PM Folegatti, M Bittaye, A Flaxman, FR Lopez, D Bellamy, A Kupke, C Mair, R Makinson, J Sheridan, C Rohde, S Halwe, Y Jeong, YS Park, JO Kim, M Song, A Boyd, N Tran, D Silman, I Poulton, M Datoo, J Marshal, Y Themistocleous, A Lawrie, R Roberts, E Berrie, S Becker, T Lambe, A Hill, K Ewer, S GilbertFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.